Best Of BIO: Policy & Regulatory Updates From BIO 2017

Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.

The gene-editing specialist Editas Medicine Inc. is working on preclinical studies to support the filing of its first investigational new drug (IND) application in mid-2018 for a therapy to treat leber congenital amaurosis 10 (LCA10). Patent disputes between two major CRISPR/Cas9 inventors have been going on while those preparations are under way, but decisions largely have been occurring in Editas's favor.

The US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) decided in February that there was "no...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet